GO:0032700 negative regulation of interleukin-17 production: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032700 describes any process that stops, prevents, or reduces the production of interleukin-17 family cytokines.
• IL-17 is a pro-inflammatory cytokine produced by a distinct lineage of CD4 T cells, now known as Th17 cells.
• Negative regulation of IL-17 production is critical for limiting tissue inflammation and preventing autoimmune pathology.
• Key negative regulators include OX40/OX40L interaction, PRELP, BTNL2, and short-chain fatty acids.
• Dysregulation of IL-17 production is linked to psoriasis, allergic asthma, cancer immune escape, and metabolic inflammation.
• CRISPR-based models (knockout, knock-in, overexpression) enable causal dissection of this regulatory process.
Description
Interleukin-17 (IL-17) is a family of pro-inflammatory cytokines that play a central role in host defense and tissue inflammation. The production of IL-17 is tightly controlled, and its negative regulation is essential to prevent excessive inflammation and autoimmunity. GO:0032700, negative regulation of interleukin-17 production, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of production of any member of the interleukin-17 family. This term is a biological process annotation that captures a wide range of molecular mechanisms, from receptor-mediated signaling to transcriptional repression. Researchers study GO:0032700 to understand how the immune system balances effective pathogen clearance with tolerance to self-tissues. The discovery of Th17 cells as a distinct lineage of CD4 T cells that produce IL-17 revolutionized the field, linking IL-17 to autoimmune diseases such as psoriasis and multiple sclerosis. Negative regulators of IL-17 production, such as OX40/OX40L interaction, have been shown to suppress IL-17 secretion and ameliorate experimental autoimmune encephalomyelitis. More recently, molecules like PRELP and BTNL2 have been identified as negative regulators in psoriasis and cancer immune escape, respectively. Understanding the negative regulation of IL-17 production has broad implications for therapeutic development. For example, short-chain fatty acids derived from gut microbiota can regulate group 3 innate lymphoid cells and IL-17 production in hepatocellular carcinoma. In allergic asthma, IL-17 itself can act as a negative regulator of established disease, highlighting the context-dependent roles of this cytokine. This article synthesizes current knowledge on GO:0032700, covering its definition, key genes, regulatory mechanisms, disease associations, and research methods including CRISPR-based models.
negative regulation of interleukin-17 production At A Glance
| GO ID | GO:0032700 |
|---|---|
| GO term | negative regulation of interleukin-17 production |
| Ontology | biological_process |
| Synonym | inhibition of interleukin-17 production; downregulation of IL-17 production; negative regulation of CTLA-8 production |
| Major function | Suppression of IL-17 family cytokine production to limit inflammation |
| Related cytokines | IL-17A, IL-17F, IL-17A/F heterodimer |
| Key cell types | Th17 cells, gamma-delta T cells, group 3 innate lymphoid cells |
| Disease relevance | Psoriasis, allergic asthma, cancer immune escape, metabolic inflammation |
What Is GO:0032700?
GO:0032700, negative regulation of interleukin-17 production, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of production of any member of the interleukin-17 family of cytokines. This includes inhibition of IL-17 biosynthesis, secretion, or overall production. The term is a biological process and is synonymous with downregulation or inhibition of IL-17 production, as well as negative regulation of CTLA-8 production or secretion.
Why Is negative regulation of interleukin-17 production Important in Cell Biology?
Negative regulation of IL-17 production is a critical checkpoint in immune homeostasis. Excessive IL-17 signaling drives chronic inflammatory and autoimmune diseases, while insufficient IL-17 can impair host defense. Understanding the molecular players that suppress IL-17 production provides therapeutic targets for modulating inflammation in diseases such as psoriasis, asthma, and cancer.
• Prevents autoimmune pathology by limiting Th17-mediated tissue damage.
• Modulates allergic asthma severity, where IL-17 can act as a negative regulator.
• Influences tumor immune surveillance and escape, as seen with BTNL2 in cancer.
• Regulates metabolic inflammation linked to diet and acne.
• Gut microbiota-derived short-chain fatty acids modulate IL-17 production in liver cancer.
• Provides targets for anti-inflammatory drug development in psoriasis.
• Balances host defense against pathogens with immune tolerance.
• Key to understanding Th17 cell biology and plasticity.
• Relevant to vaccine adjuvant design and mucosal immunity.
• Implications for inflammatory bowel disease and multiple sclerosis.
What Happens During negative regulation of interleukin-17 production?
Initiation by negative regulatory signals
In simple terms: Certain signals tell immune cells to stop making IL-17.
Negative regulation of IL-17 production can be initiated by engagement of surface receptors such as OX40 with its ligand OX40L, which delivers inhibitory signals to T cells. Other soluble factors, including short-chain fatty acids from gut microbiota, can also trigger negative regulatory pathways in group 3 innate lymphoid cells. These signals converge on intracellular cascades that ultimately suppress IL-17 gene transcription.
Transcriptional suppression of IL-17 genes
In simple terms: The cell turns down the genes that make IL-17.
At the transcriptional level, negative regulators can inhibit the activity of transcription factors such as RORgamma-t and STAT3, which are required for IL-17 expression. For example, PRELP has been shown to negatively regulate IL-17A-mediated proliferation and inflammatory responses in psoriasis, likely by interfering with downstream signaling. The exact molecular mechanisms may involve recruitment of co-repressors or epigenetic modifications.
Post-transcriptional and secretory control
In simple terms: Even if some IL-17 mRNA is made, the cell can block its release.
Negative regulation can also occur post-transcriptionally, affecting mRNA stability or protein secretion. For instance, BTNL2 expressed on cancer cells engages IL-17A-producing gamma-delta T cells and facilitates tumor immune escape, potentially by altering IL-17 secretion. However, the precise post-transcriptional mechanisms remain an active area of research.
Feedback loops and resolution of inflammation
In simple terms: The body uses feedback to keep inflammation from spiraling out of control.
IL-17 itself can act as a negative regulator in certain contexts, such as established allergic asthma, where it suppresses eosinophilic inflammation. This context-dependent feedback highlights the complexity of GO:0032700. Additionally, diet-derived metabolites like short-chain fatty acids can modulate IL-17 production, linking metabolism to immune regulation.
Key Genes Involved in GO:0032700 negative regulation of interleukin-17 production
The following genes and proteins are experimentally implicated in the negative regulation of interleukin-17 production, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| OX40L (TNFSF4) | Ligand for OX40; interaction negatively regulates IL-17 production | Shown to suppress IL-17 and ameliorate EAE |
| OX40 (TNFRSF4) | Receptor on T cells; mediates negative regulation of IL-17 | Target for modulating Th17 responses |
| PRELP | Extracellular matrix protein; negatively regulates IL-17A-mediated inflammation | Implicated in psoriasis |
| BTNL2 | Butyrophilin-like 2; cancer cell-expressed; engages gamma-delta T cells | Facilitates tumor immune escape via IL-17A |
| IL-17A | Pro-inflammatory cytokine; target of negative regulation | Central to Th17-mediated inflammation |
| IL-17F | Pro-inflammatory cytokine; member of IL-17 family | Co-regulated with IL-17A |
| RORC (RORgamma-t) | Transcription factor required for Th17 differentiation and IL-17 production | Master regulator of Th17 cells |
| STAT3 | Transcription factor downstream of IL-6/IL-23; promotes IL-17 expression | Target of negative regulation |
| IL-23R | Receptor for IL-23; sustains Th17 cells | Indirectly affects IL-17 production |
| Foxp3 | Regulatory T cell transcription factor; can suppress IL-17 | Treg-mediated suppression |
| IL-10 | Anti-inflammatory cytokine; can inhibit IL-17 production | Immunoregulatory feedback |
| TGF-beta | Cytokine with context-dependent effects on Th17 differentiation | Modulates IL-17 production |
| SCFA (butyrate, propionate) | Microbiota-derived metabolites; regulate group 3 ILCs | Linked to HCC and metabolic inflammation |
| miR-192-5p | MicroRNA in exosomes; targets IL-17RA/Smad axis | Attenuates hypertrophic scar fibrosis |
| IL-17RA | Receptor for IL-17A; mediates signaling | Target of miR-192-5p |
| Smad | Intracellular signaling proteins; downstream of TGF-beta | Modulated by miR-192-5p in fibrosis |
How Is negative regulation of interleukin-17 production Regulated?
The negative regulation of IL-17 production is controlled by a network of extracellular signals, intracellular signaling pathways, and transcriptional feedback loops. Key regulatory inputs include OX40/OX40L interaction, which suppresses IL-17 production and reduces experimental autoimmune encephalomyelitis severity. Short-chain fatty acids derived from gut microbiota regulate group 3 innate lymphoid cells and IL-17 production in hepatocellular carcinoma. Additionally, PRELP negatively regulates IL-17A-mediated proliferation and inflammatory responses in psoriasis. BTNL2 expressed on cancer cells engages IL-17A-producing gamma-delta T cells to facilitate immune escape, indicating that tumor microenvironment can modulate IL-17 production. IL-17 itself can act as a negative regulator in established allergic asthma, demonstrating context-dependent feedback. Diet and metabolic factors also influence IL-17 production, as reviewed in acne metabolomics.
negative regulation of interleukin-17 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRELP | Psoriasis | Knockout mouse or human keratinocyte cell line with PRELP overexpression |
| BTNL2 | Cancer immune escape | Tumor cell lines co-cultured with gamma-delta T cells; BTNL2 knockout |
| IL-17A | Allergic asthma | IL-17A knockout or transgenic mouse models |
| SCFA receptors (GPR43/GPR41) | Hepatocellular carcinoma | Germ-free or antibiotic-treated mouse models with SCFA supplementation |
| OX40/OX40L | Experimental autoimmune encephalomyelitis | OX40L transgenic or knockout mice |
Psoriasis and Inflammatory Skin Diseases
Psoriasis is a chronic inflammatory skin disease driven in part by IL-17-producing T cells. PRELP has been identified as a negative regulator of IL-17A-mediated proliferation and inflammatory responses in psoriasis, suggesting that loss of PRELP function may exacerbate disease. Targeting negative regulators of IL-17 production could offer therapeutic strategies for psoriasis.
Cancer Immune Escape
Cancer cells can exploit negative regulation of IL-17 production to evade immune surveillance. BTNL2 expressed on cancer cells engages IL-17A-producing gamma-delta T cells, facilitating tumor immune escape. In hepatocellular carcinoma, gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells and IL-17 production, influencing tumor progression.
Allergic Asthma
IL-17 can act as a negative regulator of established allergic asthma, suppressing eosinophilic inflammation. This context-dependent role highlights the complexity of IL-17 regulation in allergic diseases. Modulating negative regulation of IL-17 production may have therapeutic potential in asthma.
Metabolic and Diet-Related Inflammation
Dietary factors and metabolic inflammation are linked to IL-17 production. An update on acne metabolomics, inflammation, and comedogenesis discusses how diet influences inflammation, potentially through IL-17 pathways. Short-chain fatty acids from gut microbiota also modulate IL-17 production in liver cancer.
From negative regulation of interleukin-17 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate IL-17 production? | CRISPR knockout of gene X in Th17 cells followed by IL-17 ELISA |
| Does a point mutation in gene X affect its ability to suppress IL-17? | CRISPR point mutation knock-in in cell lines |
| Does overexpression of gene X reduce IL-17 in vivo? | Transgenic or viral overexpression in mouse models |
| Where is gene X expressed in relation to IL-17-producing cells? | Tagged knock-in reporter mice |
| Does gene X interact with IL-17 signaling components? | Co-immunoprecipitation and proximity labeling |
| Can CRISPR library screening identify novel negative regulators? | Genome-wide CRISPR knockout screen in Th17 cells |
How to Study the negative regulation of interleukin-17 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Secreted IL-17 protein levels | Quantifying negative regulation in cell culture |
| Flow cytometry | Intracellular IL-17 in T cell subsets | Identifying Th17 cells and gamma-delta T cells |
| RNA-seq | Transcriptome including IL17A/F mRNA | Global effects of negative regulators |
| ChIP-seq | Transcription factor binding at IL17 locus | Mechanistic studies of transcriptional repression |
| CRISPR knockout screen | Genes whose loss increases IL-17 production | Discovery of novel negative regulators |
| Co-immunoprecipitation | Protein-protein interactions | Identifying signaling complexes |
| Mouse EAE model | Autoimmune inflammation severity | Testing negative regulators in vivo |
| Airway inflammation model | Allergic asthma phenotypes | Context-dependent IL-17 effects |
Quantifying IL-17 Production
IL-17 production is commonly measured by ELISA, intracellular cytokine staining, or flow cytometry after PMA/ionomycin stimulation. These methods allow researchers to assess the effects of negative regulators on IL-17 protein levels.
Transcriptional Analysis
RNA-seq and qPCR can quantify IL17A and IL17F mRNA levels to determine whether negative regulation occurs transcriptionally. Chromatin immunoprecipitation (ChIP) can identify transcription factor binding at the IL17 locus.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens in primary T cells or cell lines can identify novel negative regulators of IL-17 production. Hits are validated by targeted knockout and IL-17 measurement.
In Vivo Models
Mouse models of autoimmune disease (e.g., EAE), allergic asthma, or cancer can be used to study negative regulation of IL-17 production in a physiological context. Adoptive transfer of gene-edited T cells is a powerful approach.
How CRISPR Can Be Used to Study GO:0032700 negative regulation of interleukin-17 production
Knockout
CRISPR knockout of candidate negative regulators (e.g., OX40, PRELP) in T cells or cell lines can determine whether they are required to suppress IL-17 production. Loss of function typically leads to increased IL-17 levels if the gene is a negative regulator.
Point Mutation
Point mutations can be introduced to disrupt specific domains or phosphorylation sites in negative regulators, allowing fine mapping of functional residues. For example, mutating the interaction interface of OX40L could abolish its ability to suppress IL-17.
Knock-in
Knock-in of reporter tags (e.g., GFP) or epitope tags into endogenous loci enables tracking of negative regulator expression and localization in live cells. This is useful for studying dynamic regulation of IL-17 production.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can drive high levels of a candidate negative regulator to test whether it is sufficient to reduce IL-17 production. This approach is valuable for therapeutic target validation.
How EDITGENE Supports negative regulation of interleukin-17 production Research
Researchers studying negative regulation of interleukin-17 production-related genes often need to determine whether a candidate gene is causally involved in suppressing IL-17. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-17 production research.
Frequently Asked Questions About negative regulation of interleukin-17 production
What is GO:0032700?
GO:0032700 is the Gene Ontology term for negative regulation of interleukin-17 production, defined as any process that stops, prevents, or reduces the production of IL-17 family cytokines.
What genes are involved in negative regulation of interleukin-17 production?
Key genes include OX40/OX40L, PRELP, BTNL2, and IL-17 itself in feedback loops, as well as transcription factors like RORgamma-t and STAT3.
How is IL-17 production negatively regulated?
Negative regulation occurs through receptor-mediated signaling (e.g., OX40/OX40L), transcriptional repression, post-transcriptional mechanisms, and feedback loops involving cytokines and metabolites.
What diseases are associated with dysregulated IL-17 production?
Psoriasis, allergic asthma, cancer immune escape, and metabolic inflammation are linked to altered negative regulation of IL-17 production.
What cell types produce IL-17?
IL-17 is primarily produced by Th17 cells, a distinct lineage of CD4 T cells, as well as gamma-delta T cells and group 3 innate lymphoid cells.
How can CRISPR be used to study negative regulation of IL-17 production?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the causal role of candidate genes in suppressing IL-17 production.
What is the role of OX40/OX40L in IL-17 regulation?
OX40/OX40L interaction negatively regulates IL-17 production and has been shown to ameliorate experimental autoimmune encephalomyelitis.
How do short-chain fatty acids affect IL-17 production?
Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells and IL-17 production in hepatocellular carcinoma.
Can IL-17 act as a negative regulator?
Yes, in established allergic asthma, IL-17 acts as a negative regulator of eosinophilic inflammation, demonstrating context-dependent roles.
What methods are used to study negative regulation of IL-17 production?
Common methods include ELISA, flow cytometry, RNA-seq, ChIP-seq, CRISPR screens, and in vivo mouse models of autoimmunity or asthma.
Conclusion
GO:0032700, negative regulation of interleukin-17 production, is a critical biological process that maintains immune homeostasis by limiting excessive IL-17-driven inflammation. Key negative regulators such as OX40/OX40L, PRELP, and BTNL2 have been identified, with implications for psoriasis, cancer, and allergic asthma. Understanding these mechanisms offers therapeutic opportunities, and CRISPR-based models are indispensable for causal dissection. EDITGENE provides comprehensive services to support such research, from knockout to library screening.
References
- 1. Melnik BC. 2015. Linking diet to acne metabolomics, inflammation, and comedogenesis: an update.. Clin Cosmet Investig Dermatol 8:371-88 PMID: 26203267
- 2. Hu C et al.. 2023. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC.. Hepatology 77(1):48-64 PMID: 35262957
- 3. Li J et al.. 2008. Negative regulation of IL-17 production by OX40/OX40L interaction.. Cell Immunol 253(1-2):31-7 PMID: 18501882
- 4. Li Y et al.. 2021. Exosomes derived from human adipose mesenchymal stem cells attenuate hypertrophic scar fibrosis by miR-192-5p/IL-17RA/Smad axis.. Stem Cell Res Ther 12(1):221 PMID: 33789737
- 5. Park H et al.. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.. Nat Immunol 6(11):1133-41 PMID: 16200068
- 6. He CC et al.. 2026. PRELP negatively regulates IL-17A-mediated proliferation and the inflammatory response in psoriasis.. Signal Transduct Target Ther 11(1) PMID: 42204138
- 7. Du Y et al.. 2022. Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells.. Nat Commun 13(1):231 PMID: 35017553
- 8. Schnyder-Candrian S et al.. 2006. Interleukin-17 is a negative regulator of established allergic asthma.. J Exp Med 203(12):2715-25 PMID: 17101734
